While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.
Eli Lilly and Company has outlined plans to develop a $3bn manufacturing facility in Katwijk, Leiden Bio Science Park, the ...
Stocktwits on MSN
Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Rise
Analysts expect Novo Nordisk’s Q3 revenue to fall 2% to $11.87 billion and earnings per share to drop as competition from Eli Lilly intensifies. ・The report marks CEO Mike Doustdar’s first since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback